PMID: 7023894Jul 1, 1981Paper

Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison

Drug and Alcohol Dependence
B A JudsonA Goldstein

Abstract

The goals of this study were two-fold: (1) to test the hypothesis that retention of patients in naltrexone treatment could be improved by educating and preparing them for it while enrolled in a LAAM (l-alpha-acetylmethadol) detoxification program; and (2) to compare the safety and efficacy of 60 mg vs. 120 mg administered thrice weekly in a double-blind, sequential trial design. Patients were allowed a maximum of 365 days on naltrexone, and a maximum of four admissions; 119 patients received at least one dose of naltrexone. We found no clinically important differences between the two dosages, and retention in treatment was similar to that reported in earlier clinical trials. Slightly more than half the patients ever used heroin while receiving naltrexone, and only 9% of all urine tests were positive for opiates. Craving for heroin decreased dramatically by the end of the first week. We found no side-effect or toxicity due to naltrexone.

References

Aug 1, 1978·The International Journal of the Addictions·D C LewisR Black
Jan 1, 1978·The American Journal of Drug and Alcohol Abuse·S I SideroffM E Jarvik
Jan 1, 1975·The American Journal of Drug and Alcohol Abuse·Z TaintorN Wicks
May 1, 1977·Drug and Alcohol Dependence·L E HollisterP Kasper
Jan 1, 1976·The International Journal of the Addictions·S M MirinM McDougle
Jan 1, 1975·The American Journal of Drug and Alcohol Abuse·C P O'BrienG E Woody

❮ Previous
Next ❯

Citations

Sep 15, 2006·Psychopharmacology·Maria A SullivanSandra D Comer
Nov 1, 1982·Peptides·G A OlsonD H Coy
Jan 1, 1984·Addictive Behaviors·J E RoseA Ertle
May 21, 1998·European Journal of Pharmacology·S D ComerM W Fischman
Apr 27, 1999·Drug and Alcohol Dependence·K L PrestonC R Schuster
Jan 23, 1998·Journal of Substance Abuse Treatment·J W CornishC P O'Brien
Jan 1, 1993·Drug and Alcohol Review·M J Christie, A I Harvey
Oct 6, 2005·Drug and Alcohol Review·A FoyA Taylor
Aug 10, 2012·Journal of Addictive Diseases·Gavin Bart
May 19, 2007·Addiction Biology·Boukje A G DijkstraCees P F van der Staak
Oct 25, 2000·Alcoholism, Clinical and Experimental Research·M R RukstalisJ R Volpicelli
Jan 1, 2010·BMJ Case Reports·Albert Stuart Reece
Jan 1, 1991·Drug Metabolism and Drug Interactions·L A PiniE Sternieri
Jan 1, 1995·Journal of Substance Abuse Treatment·G GerraM Passeri
Jan 1, 1984·The American Journal of Drug and Alcohol Abuse·E G SingletonG E Bigelow
May 17, 2007·Internal Medicine Journal·A Foy
Feb 28, 2006·Alcoholism, Clinical and Experimental Research·Bankole A JohnsonNassima Ait-Daoud
Aug 19, 2010·The American Journal on Addictions·Donna M CovielloCharles P O'Brien
Jun 9, 2004·Journal of Substance Abuse Treatment·Evgeny M KrupitskyGeorge E Woody
Jul 1, 1984·Drug and Alcohol Dependence·B A Judson, A Goldstein
Nov 7, 2006·Journal of Substance Abuse Treatment·Evgeny M KrupitskyGeorge E Woody
Jun 17, 2006·European Addiction Research·Helge WaalJørg Mørland
Sep 1, 1986·Journal of Clinical Psychology·T CaponeM Peterson
May 2, 2002·The Australian and New Zealand Journal of Psychiatry·Alison J Ritter
Sep 18, 2007·Journal of Clinical Psychopharmacology·Paolo MannelliRobert Hubbard
Mar 1, 1987·Medical Toxicology·H M Ginzburg, M G MacDonald
Sep 1, 1985·The International Journal of the Addictions·M Allison, R L Hubbard
Nov 1, 1987·Journal of Andrology·H E KulinJ D Veldhuis
Jul 1, 1990·DICP : the Annals of Pharmacotherapy·S K Guthrie
Sep 17, 2004·Drug and Alcohol Review·Thamizan TuckerHenry Jackson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.